Compliance to EU MDR will require a lot of changes in a short amount of time, from labeling to technical files to clinical evidence requirements to postmarket surveillance. “It forces you to look at your processes and see how you can do things more effectively,” according to Hilde Viroux, associate vice president, regulatory at HCL America, Inc. A variety of factors come into play in determining a company’s level of EU MDR readiness, and unfortunately, some common misconceptions that companies have can get in the way of a successful transition. During this week’s MedTech Intelligence workshop on EU MDR Implementation Strategies, Viroux provided some areas in which companies can get themselves into trouble.
Misconceptions of EU MDR Implementation Projects
We have until 2025; we don’t need to worry about it. No. By May 2020 you need to have your certifications—either renewed MDD certificates that enable the sale of product until May 2025, or certifications to MDR (all new product launches must be MDR compliant).
This is a regulatory project; let regulatory deal with it. No. This is a business project—it’s a complex project that affects all areas of the business.
Let each function deal with it separately. No. There are many different departments that must come together to form this as a project: R&D, quality, clinical, legal, IT, supply chain/operations, regulatory and HR, among them.
We will absorb the effort. No. It’s a strategic decision that every company needs to make. What impact will the new requirements have on your staff resources? Look at how the resources will be used in dealing with clinical evaluation and investigations, EUDAMED, labeling and instructions for use, and vigilance and postmarket surveillance.
Let’s jump straight into implementation. No. Viroux recommends companies take the following steps:
-Do a gap assessment to see what effort is needed and what budget is required.
-Conduct a pilot phase where you can confirm any conclusions made during the gap assessment. Test your partners, and then refine your budget.
-Implementation: Ensure senior leadership takes ownership and oversight during this phase.
-Compliance: Partner with a notified body, plan for the MDD certificate renewals and plan your MDR audits.
It’s a one-time effort. No. The efforts continue: The MDR certificate is not the end of it—it’s the start. Post activities are important, and companies will need to reopen technical files much more frequently.
The European Commission developed the new proposal following a December 9, 2022, meeting of the EPSCO Council, where EU Ministers of Health called on the Commission to swiftly submit a proposal to extend the transition period in the Medical Device…
On Monday, March 20, the EU MDR extension approved on March 7 came into effect following its official publication in the Journal of the European Union.
EU MDR has increased the regulatory burden for medical device companies, but it can also serve as a catalyst for innovation and an opportunity to streamline clinical evaluation workflows through the adoption of digitalization and AI-powered automation.
The position paper from the European Commission’s Medical Device Coordination Group (MDCG) recommends an extended timeline to allow certain MDD or AIMDD certified legacy devices to come into compliance with MDR.
Maria Fontanazza has more than 15 years of experience in journalism, marketing and communications. She was previously marketing communications manager and market research manager at Secant Medical, Inc., a manufacturer of biomedical textiles and advanced biomaterials. Fontanazza also served as an editor at MD+DI and has authored articles that have appeared in domestic and international industry publications. Fontanazza has a B.A. in Journalism and Mass Communications with a concentration in New Media and Visual Design, and a Minor in Fine Arts, from St. Michael’s College in Colchester, VT. Follow her industry insights on Twitter at @MariaFontanazza. Contact Maria